Survival of patients with chronic myelocytic leukemia: Comparisons of estimates from clinical trial settings and population-based cancer registries

Oncologist

Volumn 16, Issue 5, 2011, Pages 663-671

  Pulte, Dianne ^a,b   Gondos, Adam ^a   Redaniel, Maria Theresa ^a,c   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Chronic myelocytic leukemia; Clinical trials; SEER program; Survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON; RETINOL; TIOGUANINE;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DATA BASE; DRUG DOSE COMPARISON; DRUG INFORMATION; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL RECORDS; MIDDLE AGED; SEER PROGRAM; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 79956279101     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0393     Document Type: Article

References (39)

1. Svensson CK. Representation of American blacks in clinical trials of new drugs. JAMA 1989;261:263-265.
2. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682-1688.
3. Yessaian A, Mendivil AA, Brewster WR. Population characteristics in cervical cancer trials: Search for external validity. Am J Obstet Gynecol 2005; 192:407-413.
4. Begg CB, Engstrom PF. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol 1987;5:962-968.
5. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level. Haematologica 2008;93:1544-1549.
6. Ohnishi K, Tomonaga M, Kamada N et al. A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. Leuk Res 1998;22:779-786.
7. Gale RP, Hehlmann R, Zhang MJ et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998;91:1810-1819.
8. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355: 2408-2417.
9. Surveillance, Epidemiology, and End Results (SEER) Program Limited Use Data (1973-2006). Released April, 2009 based on November 2008 submission. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2009. Available online at http://seer.cancer.gov/data/index, accessed March 28, 2011.
10. Meyskens FL Jr, Kopecky KJ, Appelbaum FR et al. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: A SWOG randomized trial. Leuk Res 1995;19:605-612.
11. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82:398-407.
12. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-4077.
13. Rieter E, Greinix HT, Keil F et al. Long-term follow-up of patients after related-and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 1999;78:507-513.
14. Olsson-Strömberg U, Simonsson B, Ahlgren T et al. Comparison of busulphan, hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid leukemia: BMT prolongs survival. Hematol J 2004;5:462-466.
15. Kloke O, Opalka B, Niederle N. Interferon alfa as primary treatment of chronic myeloid leukemia: Long-term follow-up of 71 patients observed in a single center. Leukemia 2000;14:389-392.
16. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 1998;92:1541-1548.
17. Gratwohl A, Hermans J, van Biezen A et al. Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996;95:494-500.
18. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994;84: 4368-4373.
19. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-1397.
20. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The BeNeLux CML Study Group. Blood 1998;91:2713-2721.
21. Clift RA, Bucknew CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84:2036-2043.
22. Guilhot F, Chastang C, Michallet M et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337: 223-229.
23. Kluin-Nelemans HC, Buck G, le Cessie S et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: Prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 2004;103:4408-4415.
24. Kühr T, Burgstaller S, Apfelbeck U et al. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res 2003;27:405-411.
25. Baccarani M, Rosti G, de Vivo A et al. A randomized study of interferonalpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-1535.
26. Peñarrubria MJ, Odriozola J, Gonzalez C et al. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: No differences in cytogenetic responses. Ann Hematol 2003;82:750-758.
27. Hehlmann R, Berger U, Pfirrmann M et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109:4686-4692.
28. Deenik W, van der Holt B, Verhoef GE et al. High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. Aprospective randomized phase III study. Ann Hematol 2007;86:117-125.
29. Hochhaus A, Druker B, Sawyers C et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008;111:1039-1043.
30. Stone RM, Donohue KA, Stock W et al. A phase II study of continuous infusion of homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009;63:859-864.
31. Palandri F, Castagnetti F, Alimena G et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009;94:205-212.
32. Palandri F, Castagnetti F, Testoni N et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up. Haematologica 2008;93:1792-1796.
33. Guilhot F, Druker B, Larson RA et al. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: Results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009;94:1669-1675.
34. Palandri F, Iacobucci I, Castagnetti F et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferonalpha: 5-year outcome. Haematologica 2008;93:770-774.
35. Castagnetti F, Palandri F, Amabile M et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party. Blood 2009;113:3428-3434.
36. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect. " J Clin Epidemiol 2001;54:217-224.
37. Davis S, Wright PW, Schulman SF et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985; 56:1710-1718.
38. Kos M, Obradovic M, Mrhar A. Accessibility to targeted drugs in Slovenia and selected European countries. Eur J Cancer 2008;44:408-418.
39. Noens L, van Liedre MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009;113:5401-5411.